223 related articles for article (PubMed ID: 20014934)
21. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
[TBL] [Abstract][Full Text] [Related]
22. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
Drake WM; Stiles CE; Bevan JS; Karavitaki N; Trainer PJ; Rees DA; Richardson TI; Baldeweg SE; Stojanovic N; Murray RD; Toogood AA; Martin NM; Vaidya B; Han TS; Steeds RP; ; Baldeweg FC; Sheikh UE; Kyriakakis N; Parasuraman SK; Taylor L; Butt N; Anyiam S
J Clin Endocrinol Metab; 2016 Nov; 101(11):4189-4194. PubMed ID: 27571182
[TBL] [Abstract][Full Text] [Related]
23. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
24. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
25. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
26. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
Valassi E; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
[TBL] [Abstract][Full Text] [Related]
27. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
Cawood TJ; Bridgman P; Hunter L; Cole D
Intern Med J; 2009 Apr; 39(4):266-7. PubMed ID: 19402868
[No Abstract] [Full Text] [Related]
28. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
[TBL] [Abstract][Full Text] [Related]
29. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
[TBL] [Abstract][Full Text] [Related]
30. The cabergoline-resistant prolactinoma patient: new challenges.
Molitch ME
J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
[No Abstract] [Full Text] [Related]
31. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
[TBL] [Abstract][Full Text] [Related]
32. The safety of treatments for prolactinomas.
Auriemma RS; Grasso LF; Pivonello R; Colao A
Expert Opin Drug Saf; 2016; 15(4):503-12. PubMed ID: 26855238
[TBL] [Abstract][Full Text] [Related]
33. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
Drake WM; Stiles CE; Howlett TA; Toogood AA; Bevan JS; Steeds RP;
J Clin Endocrinol Metab; 2014 Jan; 99(1):90-6. PubMed ID: 24187407
[TBL] [Abstract][Full Text] [Related]
34. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Halperin I; Aller J; Varela C; Mora M; Abad A; Doltra A; Santos AE; Batista E; García-Pavía P; Sitges M; Mirelis JG; Lucas T; Puig-Domingo M
Clin Endocrinol (Oxf); 2012 Aug; 77(2):275-80. PubMed ID: 22288503
[TBL] [Abstract][Full Text] [Related]
35. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
37. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Lebbe M; Hubinont C; Bernard P; Maiter D
Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
[TBL] [Abstract][Full Text] [Related]
38. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
Samson SL; Ezzat S
Endocr Pract; 2014 Jun; 20(6):608-16. PubMed ID: 24969114
[TBL] [Abstract][Full Text] [Related]
39. Pituitary apoplexy associated with cabergoline therapy.
Chng E; Dalan R
J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
[TBL] [Abstract][Full Text] [Related]
40. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]